DeepMed Research

Bicalutamide

Generic Name: Bicalutamide

Brand Names: Casodex

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₄F_₄N_₂O_₄S

CAS Number: 90357-06-5

Unique Ingredient Identifier: A0Z3NAU9DP

Background: Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.

Indication: Bicalutamide is indicated in combination with a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of Stage D2 metastatic carcinoma of the prostate.

Associated Conditions: Metastatic stage D2 Prostatic carcinoma

Clinical Trials

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

Phase 3

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: TAK-700
Drug: Bicalutamide

First Posted Date: 2013-03-13

Last Posted Date: 2025-03-19

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 1313

Registration Number: NCT01809691

Locations: 🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 555 locations

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Recurrent Prostate Carcinoma
Prostate Adenocarcinoma

Interventions: Drug: Bicalutamide
Drug: Abiraterone Acetate
Drug: Degarelix
Drug: Flutamide
Drug: Goserelin Acetate
Drug: Leuprolide Acetate
Drug: Nilutamide
Drug: Prednisone

First Posted Date: 2013-02-07

Last Posted Date: 2025-02-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 310

Registration Number: NCT01786265

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Degarelix Neo-Adjuvant Radical Prostatectomy Trial

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Degarelix
Drug: Casodex
Drug: LHRH Agonist

First Posted Date: 2012-08-28

Last Posted Date: 2015-12-22

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 35

Registration Number: NCT01674270

Locations: 🇨🇦
Vancouver General Hospital, Vancouver, British Columbia, Canada
🇨🇦
University Health Network, Toronto, Ontario, Canada

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Enzalutamide
Drug: Bicalutamide

First Posted Date: 2012-08-14

Last Posted Date: 2019-01-30

Lead Sponsor: Pfizer

Target Recruit Count: 396

Registration Number: NCT01664923

Locations: 🇺🇸
Alliance Urology Specialists, PA, Greensboro, North Carolina, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
UCLA Clark Urology Clinic, Los Angeles, California, United States

and more 77 locations

TAK-700 in Castration Resistant Prostate Cancer

Phase 2

Withdrawn

Conditions: Prostate Cancer

Interventions: Drug: Bicalutamide
Drug: Orteronel

First Posted Date: 2012-08-07

Last Posted Date: 2016-06-10

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Registration Number: NCT01658527

Locations: 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪
Onze Lieve Vrouw Ziekenhuis, Aals, Belgium
🇧🇪
AZ Groeninge Kortrijk - Campus Vercruysselaan, Kortrijck, Belgium

and more 1 locations

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Cabazitaxel
Radiation: Intensity Modulated Radiation Therapy (IMRT)
Genetic: Luteinizing Hormone-Releasing Hormone (LHRH) Agonist

First Posted Date: 2011-08-19

Last Posted Date: 2025-05-15

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 20

Registration Number: NCT01420250

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Bioequivalence of Bicalutamide New Formulation in Japan

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: ICI176,334-1
Drug: Casodex 80 mg tablet

First Posted Date: 2011-08-15

Last Posted Date: 2012-01-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 102

Registration Number: NCT01416870

Bioequivalence of ICI176,334-1 in Japanese Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ICI176,334-1
Drug: Casodex 80 mg tablet

First Posted Date: 2011-08-12

Last Posted Date: 2012-05-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 48

Registration Number: NCT01415778

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

Not Applicable

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Bicalutamide
Drug: Dutasteride
Drug: Finasteride
Radiation: Radiation

First Posted Date: 2011-04-27

Last Posted Date: 2024-05-24

Lead Sponsor: University of Chicago

Target Recruit Count: 74

Registration Number: NCT01342367

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: enzalutamide
Drug: bicalutamide

First Posted Date: 2011-02-03

Last Posted Date: 2024-12-06

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 375

Registration Number: NCT01288911

Locations: 🇷🇴
Site RO3042, Bucharest, RO, Romania
🇷🇴
Site RO3039, Bucharest, RO, Romania
🇷🇴
Site RO3035, Bucharest, Romania

and more 85 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy